ASH 2022 | Genomic testing can help identify patient risk factors and guide clinical decision-making
Arnon Kater, MD, PhD, University of Amsterdam, Amsterdam, Netherlands, discusses the use and importance of genomic testing in chronic lymphocytic leukemia (CLL), highlighting that it can identify whether patients have clinically significant mutations such as TP53, del(17p), or complex karyotypes, which can then guide treatment decisions. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
Explore our dedicated feature on genomic testing in CLL here: http://bit.ly/403y417
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Abbvie, Astra Zeneca, BMS, Janssen, Roche/Genentech: Research Funding; Janssen, LAVA: Patents & Royalties: Pending; Astra Zeneca, BMS, Roche/Genentech, Janssen, Abbvie, LAVA: Membership on an entity’s Board of Directors or advisory committees; Abbvie, Astra Zeneca, Janssen: Other: Speakers fee; Amsterdam UMC, University of Amsterdam: Current Employment
